U.S. markets close in 2 hours 17 minutes
  • S&P 500

    4,230.22
    -53.52 (-1.25%)
     
  • Dow 30

    33,746.54
    -252.50 (-0.74%)
     
  • Nasdaq

    12,696.02
    -269.33 (-2.08%)
     
  • Russell 2000

    1,959.54
    -41.19 (-2.06%)
     
  • Crude Oil

    90.85
    +0.35 (+0.39%)
     
  • Gold

    1,763.20
    -8.00 (-0.45%)
     
  • Silver

    19.06
    -0.40 (-2.08%)
     
  • EUR/USD

    1.0042
    -0.0050 (-0.49%)
     
  • 10-Yr Bond

    2.9780
    +0.0980 (+3.40%)
     
  • GBP/USD

    1.1825
    -0.0108 (-0.90%)
     
  • USD/JPY

    136.8400
    +0.9780 (+0.72%)
     
  • BTC-USD

    21,456.45
    -1,950.69 (-8.33%)
     
  • CMC Crypto 200

    510.39
    -31.21 (-5.76%)
     
  • FTSE 100

    7,550.37
    +8.52 (+0.11%)
     
  • Nikkei 225

    28,930.33
    -11.77 (-0.04%)
     

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD).

  • AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it.

  • Treatment was well tolerated, with no severe or serious adverse events related to the study drug.

  • Related: Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors.

  • Drug-related adverse events were predominantly mild, and those few that were moderate in severity were all transient and reversible, with minimal or no symptomatic care.

  • No safety-related or PK/PD-related signs of neutralizing anti-drug antibodies were observed.

  • Data from the multiple ascending dose cohorts of INBRX-101 at 40, 80, and 120 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels.

  • The current standard of care, plasma-derived AAT, dosed once weekly at 60 mg/kg, achieves a Cavg of functional AAT of 17.8 µM over the weekly dosing interval.

  • INBRX-101 achieved a mean Cavg of functional AAT of 40.4 µM over the 21-day dosing interval following the third 80 mg/kg dose.

  • Price Action: INBX shares are down 10.50% at $15.16 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.